Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: EXOMIND (BTL-699-2) Active treatment for Generalized Anxiety Disorder (GAD)

The goal of this clinical trial is to learn if treatment with the BTL-699-2 device (non-invasive repetitive transcranial magnetic stimulation) can decrease anxiety symptoms in adults (aged 22 years and older) diagnosed with Generalized Anxiety Disorder (GAD). The main questions it aims to answer are: Does the accelerated treatment protocol using the BTL-699-2 device reduce self-reported anxiety symptoms (as measured by the GAD-7 scale) 3 months after the final treatment?

Official registry: https://clinicaltrials.gov/study/NCT07819773 · BTL Industries Ltd. · enrollment listed as 40

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are EXOMIND (BTL-699-2) Active treatment, or EXOMIND (BTL-699-2) Sham treatment. The registry lists allocation as randomized. The goal of this clinical trial is to learn if treatment with the BTL-699-2 device (non-invasive repetitive transcranial magnetic stimulation) can decrease anxiety symptoms in adults (aged 22 years and older) diagnosed with Generalized Anxiety Disorder (GAD).

They plan to enroll about 40 people at 3 sites. Taking part typically means using or being fitted with a device plus check-ins.

Official title (unrewritten)

Evaluation of the Efficacy and Safety of an Accelerated Protocol for Treating Generalized Anxiety Disorder Using the BTL-699-2 Device

Interventions: EXOMIND (BTL-699-2) Active treatment, EXOMIND (BTL-699-2) Sham treatment

Primary outcome (registry wording): Evaluation of the change in self-reported anxiety symptoms 3 months post-treatment.

Who it is for (from inclusion criteria)

  • Ages 22 Years to any
  • A diagnosis of GAD according to DSM-5 criteria, confirmed by a qualified clinician at screening
  • Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb
  • Subjects willing and able to abstain from partaking in any treatments other than the pre-procedure therapy regime for the treatment of anxiety, including non-invasive brain stimulation treatments other than the study procedure during study participation
  • Willingness to comply with study instructions and to return to the clinic for the required visits
  • Women of child-bearing potential\* are required to use birth control measures during the whole duration of the study
  • If applicable, subjects must be maintained on their pre-study psychotherapeutic regimen and any prescribed chronic medications at a stable therapeutic dose for ≥4 weeks prior to enrollment, with no dose or usage frequency changes permitted during the study
  • Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

3 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseRichmond, Virginia
Not a traditional drug phase: Antioxidant for Peripheral Vascular Diseases

The purpose of this research study is to examine the role oxidants, substances produced in the blood that can damage blood vessel function, may play in blood vessel function in healthy individuals as well as individuals with mental health disorders (posttraumatic stress disorder (PTSD) and/or generalized anxiety disorder (GAD)).

NCT04916327 · Official ClinicalTrials.gov record · Virginia Commonwealth University

RecruitingNot a traditional drug phaseLos Angeles, California
Not a traditional drug phase: Deep Brain Stimulation for Fear

Anxiety disorders such as post-traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD) affect a large number of individuals with a significant portion of patients failing to improve with current treatments. this study wants to understand the brain mechanisms that produce fear and anxiety in humans.

NCT05120635 · Official ClinicalTrials.gov record · Duke University

FAQ about this NCT record

Is NCT07819773 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07819773?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07819773?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary